Grigorios Siokas Buys 349,825 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 349,825 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was acquired at an average price of $0.20 per share, for a total transaction of $69,965.00. Following the transaction, the chief executive officer owned 14,597,917 shares of the company’s stock, valued at approximately $2,919,583.40. The trade was a 2.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, July 29th, Grigorios Siokas bought 766,284 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.18 per share, with a total value of $137,931.12.
• On Thursday, June 11th, Grigorios Siokas bought 218,447 shares of Cosmos Health stock. The stock was bought at an average cost of $0.21 per share, with a total value of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas purchased 701,447 shares of Cosmos Health stock. The stock was bought at an average price of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Price Performance

Shares of Cosmos Health stock traded up $0.01 during midday trading on Friday, hitting $0.21. 2,337,489 shares of the company traded hands, compared to its average volume of 4,600,464. The stock has a market cap of $12.55 million, a price-to-earnings ratio of -0.33 and a beta of 4.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.92 and a current ratio of 1.08. The firm’s fifty day moving average price is $0.23 and its 200-day moving average price is $0.33. Cosmos Health Inc. has a 12 month low of $0.16 and a 12 month high of $1.32.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. The business had revenue of $18.40 million during the quarter, compared to the consensus estimate of $17.93 million. As a group, sell-side analysts forecast that Cosmos Health Inc. will post 0.01 earnings per share for the current year.

Institutional Trading of Cosmos Health

Several hedge funds and other institutional investors have recently made changes to their positions in COSM. Renaissance Technologies LLC increased its stake in shares of Cosmos Health by 16.7% in the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after buying an additional 55,925 shares during the period. XTX Topco Ltd boosted its position in Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after buying an additional 34,117 shares during the period. Finally, Citadel Advisors LLC grew its holdings in Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares during the last quarter. 12.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cosmos Health in a research note on Monday, June 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.